733 related articles for article (PubMed ID: 8177717)
21. Pharmacokinetics, thrombogenicity and safety of a double viral inactivated factor IX concentrate compared with a prothrombin complex concentrate.
Ruiz-Sáez A; Hong A; Arguello A; Echenagucia M; Boadas A; Fabbrizzi F; Minichilli F; Bosch NB
Haemophilia; 2005 Nov; 11(6):583-8. PubMed ID: 16236107
[TBL] [Abstract][Full Text] [Related]
22. The use of facoor VIII and factor IX concentrates during surgery.
George JN; Breckenridge RT
JAMA; 1970 Nov; 214(9):1673-6. PubMed ID: 5536529
[No Abstract] [Full Text] [Related]
23. A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.
Berntorp E; Shapiro AD; Waters J; Astermark J
Haemophilia; 2014 Sep; 20(5):e362-4. PubMed ID: 25156443
[No Abstract] [Full Text] [Related]
24. Surgery in haemophilic patients with inhibitors.
Rodriguez-Merchan EC
Haemophilia; 2004 Sep; 10 Suppl 2():1-2. PubMed ID: 15385039
[No Abstract] [Full Text] [Related]
25. The manufacturing process for recombinant factor IX.
Harrison S; Adamson S; Bonam D; Brodeur S; Charlebois T; Clancy B; Costigan R; Drapeau D; Hamilton M; Hanley K; Kelley B; Knight A; Leonard M; McCarthy M; Oakes P; Sterl K; Switzer M; Walsh R; Foster W
Semin Hematol; 1998 Apr; 35(2 Suppl 2):4-10. PubMed ID: 9565160
[TBL] [Abstract][Full Text] [Related]
26. Recombinant factor IX.
White GC; Beebe A; Nielsen B
Thromb Haemost; 1997 Jul; 78(1):261-5. PubMed ID: 9198163
[TBL] [Abstract][Full Text] [Related]
27. Viral safety of plasma-derived factor VIII and IX concentrates.
Ludlam CA
Blood Coagul Fibrinolysis; 1997 Aug; 8 Suppl 1():S19-23. PubMed ID: 9351532
[TBL] [Abstract][Full Text] [Related]
28. Immune tolerance: critical issues of factor dose, purity and treatment complications.
DiMichele DM
Haemophilia; 2006 Dec; 12 Suppl 6():81-5; discussion 85-6. PubMed ID: 17123399
[TBL] [Abstract][Full Text] [Related]
29. A minipool process for solvent-detergent treatment of cryoprecipitate at blood centres using a disposable bag system.
Burnouf T; Goubran HA; Radosevich M; Sayed MA; Gorgy G; El-Ekiaby M
Vox Sang; 2006 Jul; 91(1):56-62. PubMed ID: 16756602
[TBL] [Abstract][Full Text] [Related]
30. Switching haemophilia products and inhibitor risk: a United States' perspective.
Nance D; Rodgers GM
Eur J Haematol; 2015 Apr; 94(4):283. PubMed ID: 25800968
[No Abstract] [Full Text] [Related]
31. Issues in making a therapeutic choice: recombinant and/or human-derived products.
Aledort LM
Haemophilia; 2001 Jan; 7(1):89-90. PubMed ID: 11136386
[No Abstract] [Full Text] [Related]
32. Induction of immune tolerance in hemophiliacs with inhibitors by combined treatment with i.v. IgG, cyclophosphamide and factor VIII or IX.
Nilsson IM; Berntorp E
Prog Clin Biol Res; 1990; 324():69-78. PubMed ID: 2106694
[No Abstract] [Full Text] [Related]
33. [On treatment trials of hemophiliacs with epsilon-aminocaproic acid (Epsamon)].
Fonio A
Schweiz Med Wochenschr; 1966 Dec; 96(51):1723-6. PubMed ID: 5973382
[No Abstract] [Full Text] [Related]
34. A higher than expected incidence of factor VIII inhibitors in multitransfused haemophilia A patients treated with an intermediate purity pasteurized factor VIII concentrate.
Peerlinck K; Arnout J; Gilles JG; Saint-Remy JM; Vermylen J
Thromb Haemost; 1993 Feb; 69(2):115-8. PubMed ID: 8456422
[TBL] [Abstract][Full Text] [Related]
35. Recombinant clotting factors in the treatment of hemophilia.
Lee C
Thromb Haemost; 1999 Aug; 82(2):516-24. PubMed ID: 10605745
[No Abstract] [Full Text] [Related]
36. Prevalence of IgG antibodies to human parvovirus B19 in haemophilia children treated with recombinant factor (F)VIII only or with at least one plasma-derived FVIII or FIX concentrate: results from the French haemophilia cohort.
Gaboulaud V; Parquet A; Tahiri C; Claeyssens S; Potard V; Faradji A; Peynet J; Costagliola D;
Br J Haematol; 2002 Feb; 116(2):383-9. PubMed ID: 11841442
[TBL] [Abstract][Full Text] [Related]
37. [Hemophilia and HTLV-III infection].
Lechler E
Z Hautkr; 1986 Dec; 61(23):1687-704. PubMed ID: 2949442
[TBL] [Abstract][Full Text] [Related]
38. Prophylaxis in children with haemophilia - the Polish experience.
Klukowska A; Urasinski T; Janik-Moszant A; Bobrowska H; Balwierz W; Woznica-Karczmarz I; Dobaczewski G; Wlazlowski M; Koltan A; Badowska W; Dakowicz L; Karolczyk G; Kostrzewska M; Korczowski B; Wasinski D; Pietrys D; Laguna P; Wysocka M
Haemophilia; 2014 Jan; 20(1):e108-10. PubMed ID: 24251651
[No Abstract] [Full Text] [Related]
39. [Substitutive treatment of hemopjolia A using a new factor VIII concentrate].
Allain JP; Steinbuch M; Meunier L; Muller JY; Soulier JP
Nouv Presse Med; 1976 Apr; 5(16):1047-50. PubMed ID: 1272773
[TBL] [Abstract][Full Text] [Related]
40. Monitoring of modified factor VIII and IX products.
Kitchen S; Gray E; Mertens K
Haemophilia; 2014 May; 20 Suppl 4():36-42. PubMed ID: 24762273
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
